Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) has announced a comprehensive psychedelic program for patients with mental distress associated with serious and chronic illness through its Wellness Utah and Cedar Clinical Research facilities.
The company said the program has four key initiatives, the first being a recently published safety, feasibility and efficacy study of group-administered psilocybin for depressed cancer patients which demonstrated the possible therapeutic benefits of psilocybin and the potential the group model holds for reducing the costs associated with psychedelic therapy.
Secondly, Numinus said it has completed a group ketamine-assisted therapy intervention pilot for patients suffering from chronic and serious illness which the company said showed the effectiveness of ketamine-assisted therapy in alleviating depression and psychological distress associated with these conditions.
Building on these two studies, Numinus announced an upcoming follow-up group psilocybin project that will reduce the therapist-to-patient ratio while continuing to evaluate the impact of psilocybin-assisted therapy on cancer patients with depression.
Further, the company said it has been selected to participate in the Ketamine Research Foundation's sponsored research study on ketamine to reduce end-of-life distress.
"Through our innovative psychedelic program for serious and chronic illness, Numinus is spearheading a new era of transformative care,” Dr. Paul Thielking, Numinus Chief Science Officer and Principal Investigator for the upcoming group psilocybin study, said in a statement.
"By harnessing the potential of psilocybin and ketamine-assisted therapies, we are providing hope and healing to individuals in need. We are excited to continue our innovative work and contribute to the advancement of psychedelic-assisted therapies for the betterment of patients worldwide."
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie